Comment
doi: 10.1002/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO;2-J.
Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky
- PMID: 11465728
- DOI: 10.1002/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO;2-J
Item in Clipboard
Comment
Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky
Arthritis Rheum.
2001 Jul.
No abstract available
Comment in
-
Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al.Arthritis Rheum. 2002 May;46(5):1408-9; author reply 1409. doi: 10.1002/art.10271. Arthritis Rheum. 2002. PMID: 12115253 No abstract available.
Comment on
-
Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.Arthritis Rheum. 1998 Jan;41(1):139-49. doi: 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T. Arthritis Rheum. 1998. PMID: 9433879
-
Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies.Arthritis Rheum. 2000 Nov;43(11):2381-2. doi: 10.1002/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO;2-M. Arthritis Rheum. 2000. PMID: 11083257 No abstract available.
-
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.Arthritis Rheum. 2000 Nov;43(11):2383-90. doi: 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D. Arthritis Rheum. 2000. PMID: 11083258
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
